| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-04-19 | Amryt Pharma (UK) | £10.0 million | IP0 | Rare diseases | IPO | |
| 2016-04-19 | G-Therapeutics (Switzerland) | € 26 million | series A financing round | Gimv (Belgium) INKEF Capital (The Netherlands) Wellington Partners (UK) Life Science Partners (LSP) (The Netherlands) G-Therapeutics founders/management | CNS diseases | Series A financing round |
| 2016-04-18 | AB Science (France) | € 12 million | private placement | Rare diseases - Hematological diseases - Neurodegenerative diseases | Private placement | |
| 2016-04-16 | Oasmia Pharmaceutical (Sweden) | SEK 45,5 million (€ 4.96 million) | private placement | institutional and qualified investors in Sweden | Cancer - Oncology - Veterinary medicine | Private placement |
| 2016-04-14 | Geneuro (Switzerland) | € 33 million | IPO | Institut Mérieux (France) Servier (France) new international shareholders | Autoimmune diseases - Neurodegenerative diseases | IPO |
| 2016-04-14 | Targedys (France) | €5.8 million | series A financing round | Seventure Partners (France) NCI (France) Pontifax (Israel) | Metabolic diseases | Series A financing round |
| 2016-04-14 | Molecular Partners (Switzerland) | CHF 30,000,000 | Private placement | |||
| 2016-04-12 | Forbion Capital Partners (The Netherlands) | € 183 million | fundraising | European Investment Fund (EIF) Dutch Venture Initiative (DVI), KfW (Germany) regional investment agencies, pension funds, insurance companies, leading European family offices, Charles River Laboratories (USA) Knight Therapeutics (Canada) | Fundraising | |
| 2016-04-08 | MedDay (France) | €34 million ($38.5 million) | series B financing round | Edmond de Rothschild Investment Partners (EdRIP) (France) InnoBio (France) Large Venture - Bpifrance (France) Sofinnova Partners (France) | Autoimmune diseases - Neurodegenerative diseases - Neurological diseases - Rare diseases | Series B financing round |
| 2016-04-04 | Anergis (Switzerland) | CHF 5 Million | financing round | Allergic diseases - Inflammatory diseases - Respiratory diseases | Financing round | |
| 2016-04-02 | Silence Therapeutics (UK) | £27.3 million | private placement | Private placement | ||
| 2016-03-29 | Gadeta (The Netherlands) | € 7 million | series A financing round | Baxalta Ventures (USA - MA) Utrecht Holdings (The Netherlands) Medicxi Ventures (Switzerland) founders and management | Cancer - Oncology | Series A financing round |
| 2016-03-24 | Quantum Genomics | €8.6 Million | private placement, capital increase | Cardiovascular diseases | Private placement | |
| 2016-03-24 | Iterum Therapeutics (Ireland) | $40 million | series A financing round | Frazier Healthcare Partners (USA - WA) Canaan Partners (USA - CA) Sofinnova Ventures (USA - CA) New Leaf Venture Partners (USA - CA) | Infectious diseases | Series A financing round |
| 2016-03-23 | Polyphor (Switzerland) | $3 million | grant | Cystic Fibrosis Foundation Therapeutics (USA - MD) | Rare diseases - Genetic diseases | Grant |
| 2016-03-22 | Corvus Pharmaceuticals (USA - CA) | IPO | Cancer - Oncology | IPO | ||
| 2016-03-22 | Topas Therapeutics (Germany) | € 14 million | series A financing round | Evotec (Germany) Epidarex Capital (UK) EMBL Ventures (Germany)GIMV (Belgium) | Autoimmune diseases | Series A financing round |
| 2016-03-21 | Atlantic Healthcare (UK) | $24 million | financing round | Fullbrook Thorpe Investments (UK) LDC (the private equity division of Lloyds Banking Group plc), existing investors. | Inflammatory diseases - Gastrointestinal diseases | Restructuring |
| 2016-03-18 | BerGenBio (Norway) | NOK212 million (€ 22.51 million) | capital increase | existing shareholders, including Investinor AS and Meteva AS | Cancer - Oncology | Capital increase |
| 2016-03-15 | Clinuvel (Australia) | A$8.3 million (€ 5.62 million) | private placement | Ophtalmological diseases | Private placement |
